U.S. Markets closed

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5500+0.0500 (+3.33%)
At close: 4:00PM EDT
Sign in to post a message.
  • S
    Sam A
    Floki. Contravir Pharmaceuticals worked on FV-100 to treat herpes Zoster and post herpetic neuralia and CMX157 to treat Hepatitis B. In 2016 company acquired Ciclofilin from Dr. Foster which worked with Ciclofilin inhibitors to treat liver diseases. In October 2018 Dr. Foster became CEO and in July 2019 the name changed to Hepion. For past three years HEPA has hired great people and their Phase 2a trial went very well in fact showed better results for such a short time compared to other company trials. The market for NASH is big $30 to $50 billion just in the U.S. alone. Phase 2b which whill start soon has a larger pool of patients and will focus on fibrosis biomarkers. In Phase 2b this company will use AI POWR to identify which patients will benefit from their drug. I believe the results will be good so we must wait and see and when it happens within next 18 months the stock will be much higher.
  • R
    How much do you expect stock prices to rise on Monday?
  • E
    SA Bullish article is out:

    "The next two catalysts are very close: Publication of the complete results of the Phase IIa trial (expected this September), and the start of the Phase IIb trial for next Q4."
  • R
    Easy $5 soon.. not many know
  • E
    The results are good. I took an excerpt from the news release (see below). With 100 million + cash on the balance sheet, this should be a 300 million MC right now based on this news.

    “The decline in Pro-C3 that was observed in the AMBITION trial puts us well within the range of NASH data published by other companies with later-stage NASH drug candidates,” said Hepion’s Chief Medical Officer, Todd Hobbs MD. “But notably, these declines in Pro-C3 with CRV431 occurred in only 4 weeks, compared to declines with other agents, where the changes occurred over several months.”

    “These biomarker findings offer us two important insights. First, CRV431 has sustained effects, as evidenced by the Pro-C3 changes at day 42. The long terminal half-life of CRV431 can explain these findings and, in fact, circulating blood concentrations of CRV431 are present at day 42, even though drug administration stopped on day 28,” said Hepion’s Senior VP, Clinical Pharmacology & Analytics, Patrick Mayo, PhD.

    “Second, the most recent data generated from our AMBITION trial has allowed us to put our machine learning and proprietary AI-POWR™ to work,” continued Dr. Mayo. “We have been able to construct models that may predict a priori who will respond to CRV431. In this context, we believe that we can predict how much of a reduction in ALT and Pro-C3 may be expected in any given subject, even as early as the first administered dose of CRV431. Indeed, we demonstrated that this works very elegantly in predicting ALT and Pro-C3 responses of subjects in the AMBITION trial with a high degree of accuracy. The PK-PD modeling also demonstrated great accuracy in predicting clinical response, as indicated by modeling diagnostics including predicted versus observed plots. Moreover, we have used our transcriptomics to investigate and construct a network of genes that gave us a very consistent picture of antifibrotic effects when CRV431 was tested in the latest clinical program. Interestingly, we also looked at these same genes in our preclinical animal models, our cellular assays, and our studies of human liver slices, and we observed the same findings with the collagen-related gene network.”
  • A
    Abel David
    ⏳📈💰 I.S.T. NEWS ALERT
    👉 $HEPA Hepion Pharmaceuticals, Inc. is scheduled to release additional data from its Phase 2a ‘AMBITION' NASH clinical trial of CRV431 before the market opens Monday, Sept. 13,
  • s
    ONTX releases a PR with positive results soars 30% HEPA releases a PR with positive results and here we are down 10%
  • B
    I think the problem here is Dilution still from the last offering and on top of that they want to add 200mil more shares. Whats This CFO Doing???
  • B
    So additional data from already released results to be released pre-market on Monday.
  • j
    It will take a little more time, but I do not remember reading a negative clinical trial data release, relative to the NASH studies. There are no approved drugs for NASH, although ICPT has been trying for many years. Thus I believe the street is skeptical. However, once HEPA reports data backed by actual patient liver biopsies (gold standard), this stock will go parabolic IMO.
  • E
    U.S. patent application number 17/184433 was filed with the patent office on 2021-09-02 for use of cyclosporine analogues for treating cancer. The applicant listed for this patent is Hepion Pharmaceuticals, Inc.. Invention is credited to Robert T. Foster, Patrick R. Mayo, Daniel J. Trepanier, Daren R. Ure.

  • p
    🚀🚀🚀 to the moon
  • A
    Over $2 by Wednesday.
    Don't Sell . Hold tight
  • E
    "U.S. patent application number 17/179406 was filed with the patent office on 2021-08-26 for use of cyclosporine analogues for treating fibrosis. The applicant listed for this patent is Hepion Pharmaceuticals, Inc.. Invention is credited to Robert T. Foster, Patrick R. Mayo, Daniel J. Trepanier, Daren R. Ure."
  • J
    ICPT 4 years ago jump to $450.00 in one day news like the one to be released monday premarket
  • A
    Nice after hours action.
    Monday could be awesome. GLTA.
  • K
    Not going to lie I started investing in this because my friend talked to some guy in a green delorean briefly who when asked about investment advice told him to invest in HEPA I’m still waiting for these returns a year later starting to think his car was rented and a got Rick rolled lol
  • m
    Thank god hepion! About time !